Incyte, CV Therapeutics Expand Heart Disease Collaboration | GenomeWeb

NEW YORK, Aug 27 – Incyte and CV Therapeutics said Monday they had agreed to work together to study the role genes play in heart disease, expanding a joint research effort that began in 1998.

Under the terms of the new agreement, the companies, both of Palo Alto, Calif., said they would focus on pinpointing genes associated with atherosclerosis and coronary artery disease.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.